Drugs / RV299
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06067191 | Aug → Dec 2022 | respiratory syncytial virus infectious disease | Pfizer | Completed | Met primary |
| Phase 1 | NCT06033612 | Nov 2021 → Jul 2022 | respiratory syncytial virus infectious disease | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RV299 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06067191 ↗ |
| Route | Oral | “Orally Administered RV299” NCT06033612 ↗ |